Trastuzumab Pamirtecan

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated, via a cleavable linker, to the cytotoxic DNA topoisomerase I inhibitor P1003, with potential antineoplastic activity. Upon administration of trastuzumab pamirtecan, trastuzumab targets and binds to HER2 expressed on tumor cells. Upon cellular uptake and internalization, P1003 is released and inhibits DNA topoisomerase 1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing HER2. HER2, a receptor tyrosine kinase that is mutated or overexpressed in many tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.

**Synonyms:** - ADC DB-1303 - Anti-HER2 ADC DB-1303 - Anti-HER2 Antibody-drug Conjugate DB-1303 - BNT 323 - BNT-323 - BNT323 - DB 1303 - DB-1303 - DB1303 - DITAC DB-1303 - TRASTUZUMAB PAMIRTECAN